Excelsior Medical Co., Ltd. (TPE:4104)
Taiwan · Delayed Price · Currency is TWD 77.90
+0.40 (0.52%)
Apr 2, 2026, 1:30 PM CST
Excelsior Medical Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 8,789 | 8,539 | 8,233 | 7,187 | 6,573 |
| 8,789 | 8,539 | 8,233 | 7,187 | 6,573 | |
Revenue Growth (YoY) | 2.94% | 3.71% | 14.56% | 9.34% | -1.53% |
Cost of Revenue | 6,915 | 6,757 | 6,564 | 5,673 | 5,199 |
Gross Profit | 1,874 | 1,781 | 1,670 | 1,514 | 1,374 |
Selling, General & Admin | 1,149 | 1,032 | 973.59 | 893.28 | 770.54 |
Other Operating Expenses | 1.74 | -4.14 | -5.85 | 0.93 | 1.41 |
Operating Expenses | 1,147 | 1,028 | 966.84 | 907.43 | 779 |
Operating Income | 727.54 | 753.32 | 702.88 | 606.61 | 595.03 |
Interest Expense | -22.14 | -18.65 | -14.32 | -5.93 | -3.65 |
Interest & Investment Income | 84.95 | 93.56 | 78.85 | 44.99 | 30.01 |
Earnings From Equity Investments | 401.42 | 323.19 | 342.3 | 290.24 | 233.43 |
Currency Exchange Gain (Loss) | -17.29 | 8.15 | -1.62 | 7.78 | -0.95 |
Other Non Operating Income (Expenses) | 7.42 | 14.03 | 16.26 | 21.22 | 25.14 |
EBT Excluding Unusual Items | 1,182 | 1,174 | 1,124 | 964.9 | 879.01 |
Gain (Loss) on Sale of Investments | - | - | -0.69 | -1.76 | -6.64 |
Gain (Loss) on Sale of Assets | - | 0.76 | 20.42 | 0.16 | -0.01 |
Other Unusual Items | - | - | - | 0.4 | 1.37 |
Pretax Income | 1,182 | 1,174 | 1,144 | 963.7 | 873.74 |
Income Tax Expense | 216.3 | 203.31 | 221.23 | 178.4 | 151.45 |
Earnings From Continuing Operations | 965.61 | 971.06 | 922.85 | 785.3 | 722.29 |
Minority Interest in Earnings | -159.75 | -199.8 | -176.25 | -117.85 | -115.14 |
Net Income | 805.86 | 771.26 | 746.61 | 667.45 | 607.15 |
Net Income to Common | 805.86 | 771.26 | 746.61 | 667.45 | 607.15 |
Net Income Growth | 4.49% | 3.30% | 11.86% | 9.93% | 6.21% |
Shares Outstanding (Basic) | 172 | 172 | 172 | 172 | 172 |
Shares Outstanding (Diluted) | 172 | 172 | 172 | 172 | 172 |
Shares Change (YoY) | 0.04% | -0.01% | -0.09% | -0.05% | 0.34% |
EPS (Basic) | 4.70 | 4.50 | 4.35 | 3.89 | 3.54 |
EPS (Diluted) | 4.68 | 4.48 | 4.33 | 3.87 | 3.52 |
EPS Growth | 4.46% | 3.38% | 11.88% | 10.16% | 5.78% |
Free Cash Flow | -1,441 | 2,357 | -19.27 | 465.53 | 780.36 |
Free Cash Flow Per Share | -8.37 | 13.68 | -0.11 | 2.70 | 4.52 |
Dividend Per Share | 4.300 | 3.800 | 3.447 | 3.153 | 2.879 |
Dividend Growth | 13.16% | 10.25% | 9.31% | 9.50% | -0.00% |
Gross Margin | 21.33% | 20.86% | 20.28% | 21.07% | 20.90% |
Operating Margin | 8.28% | 8.82% | 8.54% | 8.44% | 9.05% |
Profit Margin | 9.17% | 9.03% | 9.07% | 9.29% | 9.24% |
Free Cash Flow Margin | -16.40% | 27.60% | -0.23% | 6.48% | 11.87% |
EBITDA | 923.86 | 946.62 | 866.09 | 741.45 | 717.68 |
EBITDA Margin | 10.51% | 11.09% | 10.52% | 10.32% | 10.92% |
D&A For EBITDA | 196.32 | 193.3 | 163.21 | 134.84 | 122.65 |
EBIT | 727.54 | 753.32 | 702.88 | 606.61 | 595.03 |
EBIT Margin | 8.28% | 8.82% | 8.54% | 8.44% | 9.05% |
Effective Tax Rate | 18.30% | 17.31% | 19.34% | 18.51% | 17.33% |
Advertising Expenses | 762 | 660.34 | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.